Cheng-Hsiang Chu

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 3

Top Topics

Glycemic Control

Tyrosine Kinase

Epidermal Growth Factor Receptor

Top Venues

Therapeutic advances in medical oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Jeng-Sen Tseng, Jeng-Sen Tseng, Zhe-Rong Zheng, Cheng-Hsiang Chu, Kun-Chieh Chen, Mong-Wei Lin, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Tsung-Ying Yang, Sung-Liang Yu, Jin-Shing Chen, Chao-Chi Ho, Gee-Chen Chang
Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR -mutant lung adenocarcinoma treated with first-line osimertinib. Therapeutic advances in medical oncology 16 (2024)
Jeng-Sen Tseng, Jeng-Sen Tseng, Zhe-Rong Zheng, Cheng-Hsiang Chu, Kun-Chieh Chen, Mong-Wei Lin, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Tsung-Ying Yang, Sung-Liang Yu, Jin-Shing Chen, Chao-Chi Ho, Gee-Chen Chang
Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR -mutant lung adenocarcinoma treated with first-line osimertinib. Therapeutic advances in medical oncology 16 (2024)
Cheng-Hsiang Chu, Yen-Hsiang Huang, Po-Hsin Lee, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeng-Sen Tseng, Tsung-Ying Yang, Gee-Chen Chang
Various impacts of driver mutations on the PD-L1 expression of NSCLC. PloS one 17 (8) (2022)